Huaxia Eye Hospital Group Co Ltd
SZSE:301267
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Huaxia Eye Hospital Group Co Ltd
EPS (Diluted)
Huaxia Eye Hospital Group Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Huaxia Eye Hospital Group Co Ltd
SZSE:301267
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
A
|
Aier Eye Hospital Group Co Ltd
SZSE:300015
|
EPS (Diluted)
¥0
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
13%
|
|
|
INKON Life Technology Co Ltd
SZSE:300143
|
EPS (Diluted)
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-16%
|
CAGR 10-Years
8%
|
|
|
I
|
Innovative Medical Management Co Ltd
SZSE:002173
|
EPS (Diluted)
¥0
|
CAGR 3-Years
10%
|
CAGR 5-Years
44%
|
CAGR 10-Years
1%
|
|
|
X
|
XiAn International Medical Investment Co Ltd
SZSE:000516
|
EPS (Diluted)
¥0
|
CAGR 3-Years
32%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sanbo Hospital Management Group Ltd
SZSE:301293
|
EPS (Diluted)
¥0
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Huaxia Eye Hospital Group Co Ltd
Glance View
Huaxia Eye Hospital Group Co Ltd has positioned itself as a key player in China’s healthcare landscape, specializing in comprehensive ophthalmic services. Emerging from the early stirrings of China's reforms in the healthcare sector, Huaxia capitalized on a burgeoning demand for specialized medical care. With roots tracing back to when accessible eye care was a luxury in China, Huaxia recognized the immense potential in providing quality eye treatments. As the country urbanized rapidly, vision ailments became increasingly prevalent, creating a vast market for ocular health services. Huaxia seized this opportunity by establishing a network of state-of-the-art facilities across major cities, providing services ranging from basic eye examinations to complex surgeries. The company's revenue model is built on a multifaceted approach, combining patient volume with specialized treatments. Catering to a diverse demographic, Huaxia offers tiered service options that suit various financial capacities, ensuring a steady stream of income. Beyond individual consultations, the company has fostered partnerships with corporations and insurance providers, further securing a stable client base. Moreover, Huaxia invests significantly in pioneering medical technology and staff training, enhancing its reputation and thereby drawing more patients seeking top-notch care. Through strategic expansion and consistently leveraging advancements in ophthalmology, Huaxia Eye Hospital Group Co Ltd has solidified its place not just as a healthcare provider, but as a critical architect shaping the future of eye care in China.
See Also
What is Huaxia Eye Hospital Group Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.5
CNY
Based on the financial report for Dec 31, 2024, Huaxia Eye Hospital Group Co Ltd's EPS (Diluted) amounts to 0.5 CNY.
What is Huaxia Eye Hospital Group Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
6%
Over the last year, the EPS (Diluted) growth was -35%. The average annual EPS (Diluted) growth rates for Huaxia Eye Hospital Group Co Ltd have been -2% over the past three years , 6% over the past five years .